Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study
Authors:
Open Access
- 9 August 2024
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 25 (1) , 1-11
Abstract
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors marked a milestone in the breast cancer treatment. Due to the potential impact of adverse effects on treatment decisions and patient outcomes, careful consideration of the varying toxicities of CDK4/6 inhibitors is crucial, as three inhibitors—palbociclib, abemaciclib, and ribociclib—have been approved with differences in adverse event profiles. However, limitations in clinical trials call for urgent real-world safety studies to evaluate and compare the risk of adverse events (AEs) among these CDK4/6 inhibitors. Therefore, this study aimed to analyze AEs of CDK4/6 inhibitors and provide insights for clinical drug selection, using real world database. The AEs of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (2015–2022) were analyzed. Four disproportionality methods were used to detect safety signals: reporting odds ratio (ROR), proportional reporting ratio, Bayesian Confidence Neural Network Propagation, and Multi-Item Gamma Poisson Shrinker. Venn analysis was used to compare and select common and specific AEs. This study included 73,042 patients treated with palbociclib, 25,142 with ribociclib, and 7563 with abemaciclib. All three inhibitors had 27 common AEs. Palbociclib exhibited the highest ROR for hematologic toxicities, while ribociclib showed the highest ROR for macrocytosis, nail disorders, and hepatic lesions. Abemaciclib displayed the highest ROR for mucosal toxicity. Common signals for both palbociclib and ribociclib included hematologic toxicities, decreased immune responsiveness, and aphthous ulcers. Myelosuppression, oral pain, and pseudocirrhosis were common signals for palbociclib and abemaciclib. Anemia, hepatotoxicity, and pneumonitis were observed as common signals for ribociclib and abemaciclib. Furthermore, specific AEs associated with palbociclib included fatigue, alopecia, and stomatitis. For ribociclib, specific AEs included electrocardiogram QT prolongation, thrombocytopenia, and decreased hemoglobin. Abemaciclib was specifically linked to diarrhea, vomiting, and interstitial lung disease. Our analysis revealed that palbociclib showed a higher risk of hematologic toxicity. Ribociclib showed higher risks of hepatotoxicity, nephrotoxicity, and QT prolongation. Abemaciclib showed higher risks of hepatotoxicity, gastrointestinal effects, interstitial lung disease, and thrombosis. These findings provide valuable insights for CDK4/6 inhibitor selection.Keywords
Funding Information
- National Natural Science Foundation of China (82304629)
- Natural Science Foundation of Xiamen Municipality (3502Z202371048)
This publication has 35 references indexed in Scilit:
- Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System DatabaseThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in EudravigilanceDrug Safety, 2021
- Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast CancerClinical Breast Cancer, 2021
- Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic ReviewDrug Safety, 2021
- Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatmentsCancer Reports, 2021
- Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentBreast Cancer Research and Treatment, 2020
- Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast CancerJAMA Network Open, 2020
- Breast Cancer TreatmentJAMA, 2019
- Physiologically Based Pharmacokinetic Modeling of PalbociclibThe Journal of Clinical Pharmacology, 2016
- CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem CellsCell Stem Cell, 2015